**SURGIFLO® Hemostatic Matrix**

- SURGIFLO® fills and envelops bleeding sites **to stop bleeding fast**
- SURGIFLO® enables utilization of your own thrombin for **cost savings**
- SURGIFLO® maintains uniform viscosity better from beginning to end than FLOSEAL™

*Based on in vitro viscosity testing of SURGIFLO® 8 mL and FLOSEAL Hemostatic Matrix 5 mL, each product was prepared following Instructions for Use.

<table>
<thead>
<tr>
<th>Ordering Code</th>
<th>Size</th>
<th>Package</th>
</tr>
</thead>
<tbody>
<tr>
<td>2991</td>
<td>8 mL SURGIFLO® Hemostatic Matrix</td>
<td>Case of 6</td>
</tr>
<tr>
<td>MS1995</td>
<td>34 cm Endoscopic Applicator</td>
<td>Case of 6</td>
</tr>
</tbody>
</table>

For technical support, call 1-877-ETHICON (384-4266). For additional information, visit www.ethicon.com. Call 1-800-255-2500 to order.

**SURGIFLO® Hemostatic Matrix Essential Product Information (Made from Absorbable Gelatin Sponge, USP)**

**DESCRIPTION**
SURGIFLO® Hemostatic Matrix is intended for hemostatic use by applying to a bleeding surface.

**ACTIONS**
When used in appropriate amounts SURGIFLO® Hemostatic Matrix is absorbed completely within 4 to 6 weeks.

**INTENDED USE/INDICATIONS**
SURGIFLO® Hemostatic Matrix, mixed with with sterile saline or thrombin solution, is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or other conventional methods is ineffective or impractical.

**CONTRAINDICATIONS**
- Do not use SURGIFLO® Hemostatic Matrix in intravascular compartments because of the risk of embolization.
- Do not use SURGIFLO® Hemostatic Matrix in patients with known allergies to porcine gelatin.
- Do not use SURGIFLO® Hemostatic Matrix in closure of skin incisions because it may interfere with the healing of skin edges. This interference is due to mechanical interposition of gelatin and is not secondary to intrinsic interference with wound healing.

**WARNINGS**
- SURGIFLO® Hemostatic Matrix should not be used in the presence of infection and should be used with caution in contaminated areas of the body.
- SURGIFLO® Hemostatic Matrix should not be used in instances of pumping arterial hemorrhage. SURGIFLO® Hemostatic Matrix will not act as a tampon or plug in a bleeding site.
- SURGIFLO® Hemostatic Matrix should be removed from the site of application when used in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm because it may swell resulting in nerve damage.
- Excess SURGIFLO® Hemostatic Matrix should be removed once hemostasis has been achieved.
- The safety and effectiveness of SURGIFLO® Hemostatic Matrix for use in ophthalmic procedures has not been established.
- SURGIFLO® Hemostatic Matrix should not be used for controlling post-partum intrauterine bleeding or menorrhagia.
- The safety and effectiveness of SURGIFLO® Hemostatic Matrix has not been established in children and pregnant women.
- The blue flexible applicator tip should not be trimmed to avoid exposing internal guidewire.
- The white straight applicator tip should be trimmed away from the surgical area. Cut a square angle to avoid creating a sharp tip.

**PRECAUTIONS**
- Safe and effective use of SURGIFOAM® Sponge has been reported in a published neurologic retrospective study involving 1700 cases in Europe. Safe and effective use in neurosurgery has not been proven through randomized, controlled clinical studies in the United States.

- SURGIFLO® Hemostatic Matrix is supplied as a sterile product and cannot be resterilized.
- SURGIFLO® Hemostatic Matrix should not be used for packing unless excess product that is not needed to maintain hemostasis is removed. SURGIFLO® Hemostatic Matrix may swell up to 20% upon contact with additional fluid.
- SURGIFLO® Hemostatic Matrix should not be used in conjunction with autologous blood salvage circuits.
- SURGIFLO® Hemostatic Matrix should not be used in conjunction with methylmethacrylate adhesives.
- In urological procedures, SURGIFLO® Hemostatic Matrix should not be left in the renal pelvis or ureters to eliminate the potential foci for calculus formation.

**ADVERSE EVENTS**
A total of 142 patients received SURGIFOAM® Sponge during a clinical trial comparing SURGIFOAM® Sponge to another absorbable gelatin sponge. In general, the following adverse events have been reported with the use of absorbable porcine gelatin-based hemostatic agents.

- Gelatin-based hemostatic agents may serve as a nidus for infection and abscess formation and have been reported to potentiate bacterial growth.
- Giant cell granulomas have been observed at implant sites when used in the brain.
- Compression of the brain and spinal cord resulting from the accumulation of sterile fluid have been observed.
- Multiple neurologic events were reported when absorbable gelatin-based hemostatic agents were used in laminectomy operations, including cauda equina syndrome, spinal stenosis, meningitis, arachnoiditis, headaches, paresthesias, pain, bladder and bowel dysfunction, and impotence.
- The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg paresthesias, neck and back pain, bladder and bowel incontinence, cauda equina syndrome, neurogenic bladder, impotence, and paresis.
- The use of absorbable gelatin-based hemostatic agents has been associated with paralysis, due to device migration into foramina in the bone around the spinal cord, and blindness, due to device migration in the orbit of the eye, during lobectomy, laminectomy, and repair of a frontal skull fracture and lacerated lobe.
- Foreign body reactions, "encapsulation" of fluid, and hematoma have been observed at implant sites.
- Excessive fibrosis and prolonged fixation of a tendon have been reported when absorbable gelatin-based sponges were used in severed tendon repair.
- Toxic shock syndrome was reported in association with the use of absorbable gelatin-based hemostats in nasal surgery.
- Fever, failure of absorption, and hearing loss have been observed when absorbable hemostatic agents were used during tympanoplasty.

064302-200513